Ignite Creation Date:
2024-05-05 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00524381
Status:
COMPLETED
Last Update Posted:
2010-02-23
First Post:
2007-08-30
Brief Title:
Etanercept Treatment in the Early Course of Polymyalgia Rheumatica
Sponsor:
Bispebjerg Hospital
Organization:
Bispebjerg Hospital
Study Overview
Official Title:
The Effect of Etanercept on the Early Clinical Course of Polymyalgia Rheumatica Pilot Study
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effect of the tumor necrosis factor alpha TNF antagonist etanercept on the early clinical course of polymyalgia rheumatica PMR
PMR is a common inflammatory disease with an unknown etiology that is characterized by aching tender and stiff proximal muscle Some evidence suggests that TNF plays a central role in the pathophysiology of PMR
The preferred treatment with glucocorticoids GCs is adequate for most patients but a subset of patients have a more prolonged relapsing disease course These patients require treatment with GCs for 1 to 2 years GC related adverse events are frequent during treatment
PMR is a common inflammatory disease with an unknown etiology that is characterized by aching tender and stiff proximal muscle Some evidence suggests that TNF plays a central role in the pathophysiology of PMR
The preferred treatment with glucocorticoids GCs is adequate for most patients but a subset of patients have a more prolonged relapsing disease course These patients require treatment with GCs for 1 to 2 years GC related adverse events are frequent during treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None